Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics (NQ: CYTK )

62.90 +1.58 (+2.58%)
Streaming Delayed Price Updated: 11:31 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics

< Previous 1 2 3 4 5 6 Next >
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate
Via Benzinga
Where Cytokinetics Stands With Analysts
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug
The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug. 
Via Investor's Business Daily
Top Stories Today: Jack Dorsey Not Exactly Impressed With Elon Musk's Twitter; Binance Sees $3B Outflow In 7 Days..
Benzinga 
Via Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Analyst Ratings for Cytokinetics
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Where Cytokinetics Stands With Analysts
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306%
Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20... 
Via Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. 
Via Benzinga
Swing Trading Stock Watchlist For The Week Of Sept. 6
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look. 
Via Talk Markets
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
What 5 Analyst Ratings Have To Say About Cytokinetics
Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter: 
Via Benzinga
Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M
Via Benzinga
Recap: Cytokinetics Q2 Earnings
Cytokinetics (NASDAQ:CYTK) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics beat estimated... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
What 5 Analyst Ratings Have To Say About Cytokinetics
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: 
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing... 
Via Talk Markets
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
Exposures Product Safety
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Biggest Price Target Changes For Monday
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. 
Via Benzinga
Cytokinetics: Q1 Earnings Insights
Cytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.